Quick Answer
Corbus Pharmaceuticals Holdings, Inc. reported Stockholders Equity of $147.50 million for the year ending 2025.
- Corbus Pharmaceuticals Holdings, Inc. showed an increase of +3.6% in Stockholders Equity from 2024 to 2025.
- This data is from Corbus Pharmaceuticals Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $7.02 million | Q1 2015: $4.69 million | Q2 2015: $6.77 million | Q3 2015: $11.17 million | Q1 2016: $6.40 million | Q2 2016: $17.65 million | Q3 2016: $13.31 million | Q1 2017: $43.59 million | Q2 2017: $37.59 million | Q3 2017: $31.98 million | Q1 2018: $65.54 million | Q2 2018: $55.49 million | Q3 2018: $42.87 million | Q1 2019: $42.30 million | Q2 2019: $47.37 million | Q3 2019: $29.64 million | Q1 2020: $22.69 million | Q2 2020: $48.41 million | Q3 2020: $29.23 million | Q1 2021: $91.52 million | Q2 2021: $76.96 million | Q3 2021: $77.63 million | Q1 2022: $61.16 million | Q2 2022: $49.47 million | Q3 2022: $41.95 million | Q1 2023: $16.46 million | Q2 2023: $9.52 million | Q3 2023: $312.0 thousand | Q1 2024: $96.97 million | Q2 2024: $125.54 million | Q3 2024: $150.50 million | Q1 2025: $127.11 million | Q2 2025: $110.99 million | Q3 2025: $92.15 million.
- Over the full 13 years of available data (2013 to 2025), Corbus Pharmaceuticals Holdings, Inc.'s Stockholders Equity has grown by 8,371.8%.
- Historical annual values: Fiscal year 2025: $147.50 million | Fiscal year 2024: $142.43 million | Fiscal year 2023: -$6.91 million | Fiscal year 2022: $32.99 million | Fiscal year 2021: $69.11 million | Fiscal year 2020: $45.27 million | Fiscal year 2019: $6.16 million | Fiscal year 2018: $27.52 million | Fiscal year 2017: $57.78 million | Fiscal year 2016: $8.92 million | Fiscal year 2015: $8.99 million | Fiscal year 2014: $5.86 million | Fiscal year 2013: -$1.78 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: